Skip Navigation


NDT Plus Advance Access originally published online on February 18, 2009
NDT Plus 2009 2(3):225-227; doi:10.1093/ndtplus/sfp020
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow All Versions of this Article:
2/3/225    most recent
sfp020v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Schless, B.
Right arrow Articles by Czock, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Rituximab in two cases of Goodpasture's syndrome

Birgit Schless1, Suzan Yildirim1, Daniel Beha1, Frieder Keller1 and David Czock2

1 Division of Nephrology, Medical Department, University Hospital, Ulm
2 Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany

Correspondence: Correspondence and offprint requests to: Frieder Keller, Division of Nephrology, Medical Department I, University Hospital, Albert Einstein Allee 23, D-89070 Ulm, Germany. Tel: +49-731-500-44561; Fax: +49-731-500-44567; E-mail: frieder.keller{at}uniklinik-ulm.de


  Abstract

We describe the effects of rituximab in two patients with refractory Goodpasture's syndrome. After one single 1000 mg dose administration, rituximab did not appear to improve renal function in either of our cases. Polyoma virus-negative leukoencephalopathy, a probable toxic side effect of rituximab, was seen in our first patient.

Key Words: anti-GBM disease • Goodpasture’s syndrome • leukoencephalopathy • plasma exchange • rituximab

Received for publication January 13, 2009. Accepted for publication January 30, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.